TerminatedPhase 3NCT00009906
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
Studying Gastrointestinal stromal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- George Demetri, MDSWOG Cancer Research Network
- Intervention
- Imatinib Mesylate(drug)
- Enrollment
- 748 target
- Eligibility
- 15 years · All sexes
- Timeline
- 2000 – 2014
Study locations (30)
- Western Regional CCOP, Phoenix, Arizona, United States
- University of Arizona Health Sciences Center, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Highlands Oncology Group-Rogers, Rogers, Arkansas, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Long Beach Community Hospital, Long Beach, California, United States
- University of Southern California/Norris Cancer Center, Los Angeles, California, United States
- University of California at Los Angeles Health System, Los Angeles, California, United States
- Sutter Cancer Research Consortium, Novato, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Kaiser Permanente - Sacramento, Sacramento, California, United States
- University of California San Diego, San Diego, California, United States
- UCSF Medical Center-Mount Zion, San Francisco, California, United States
- Santa Rosa Memorial Hospital, Sana Rosa, California, United States
- Stanford University Hospitals and Clinics, Stanford, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Eastern Cooperative Oncology Group · SWOG Cancer Research Network · NCIC Clinical Trials Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00009906 on ClinicalTrials.govOther trials for Gastrointestinal stromal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego
- RECRUITINGNANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPHASE1NCT06655246A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Kura Oncology, Inc.
- RECRUITINGNANCT06926374Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic SurgeryChinese University of Hong Kong
- RECRUITINGNANCT07411118RCT of EFTR Versus STER for GIST TreatmentChinese University of Hong Kong
- RECRUITINGPHASE1, PHASE2NCT06630234A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)Deciphera Pharmaceuticals, LLC
- RECRUITINGPHASE3NCT06640361A Study of Olverembatinib in SDH-deficient GIST.Ascentage Pharma Group Inc.